Indications for BONIVA INJECTION:
Prevention and treatment of postmenopausal osteoporosis.
Limitations of Use:
Optimal duration of use has not been determined. For patients at low-risk for fracture: consider drug discontinuation after 3–5yrs.
Must be given by healthcare professional. Give as IV bolus inj over 15–30secs. 3mg every 3 months; if dose is missed, give as soon as possible, then every 3 months from the date of last inj.
BONIVA INJECTION Contraindications:
Hypocalcemia. Tabs: Esophagus abnormalities which delay esophageal emptying (eg, stricture, achalasia). Inability to stand or sit upright for at least 60mins.
BONIVA INJECTION Warnings/Precautions:
Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Severe renal impairment (CrCl <30mL/min): not recommended. Correct preexisting hypocalcemia, other mineral or bone disturbances before starting. Risk of osteonecrosis of the jaw; consider discontinuing therapy during invasive dental procedures (eg, tooth extraction, implants, surgery). History of bisphosphonate exposure: evaluate for atypical fractures if thigh/groin pain develops; consider withholding therapy until risk/benefit assessment. Ensure adequate Vit. D and calcium intake. Reevaluate periodically. Inj: check renal function before each dose. Pregnancy. Nursing mothers.
BONIVA INJECTION Classification:
BONIVA INJECTION Interactions:
Calcium, aluminum, magnesium, other multivalent cations reduce absorption (separate dosing by at least 60mins). Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Inj: concomitant nephrotoxic agents; monitor for renal toxicity.
Back pain, dyspepsia, pain in extremity, diarrhea, headache, myalgia; musculoskeletal pain (discontinue if severe), esophagitis, esophageal or gastric ulcer, jaw osteonecrosis, atypical femur fractures. Inj: inj site reactions, flu-like syndrome, anaphylaxis.
Generic Drug Availability:
Blister pack—3; Kit—1 (prefilled syringe + supplies)